What’s been going on in the life sciences world this week? Check out Week in Brief for an overview of the biggest news from ...

The BabySeq project was a first-of-its-kind initiative that used a randomised clinical trial format to assess the utility of genomic sequencing to identify disease risk in newborns.

This feature explores The Role of Biologists in the Age of AI Foundational Models. Find our more in our upcomind Multi-Omics ...

In our latest feature, we explore the future of gene editing and the challenges we must overcome to harness its full potential.

Currently, Illumina is comfortably the largest gene-sequencing company. But how did Illumina manage to monopolise the gene-sequencing market?

The science of tardigrades has come a long way in the last couple of decades – and their genomes are key to unravelling the mystery.

It is now possible to sequence an entire genome in just one day, due to the advent of next generation sequencing (NGS).

A new system that classifies genetic mutations that are likely treatable by a therapy that uses splice-switching antisense oligonucleotides (ASOs).

Single-cell RNA sequencing (scRNA-seq) has become the most established and widely used technique within single-cell analysis. Spatial transcriptomics is quickly following in the footsteps of scRNA-seq ...

New research has uncovered the function of red blood cells as immune sensors that detect and bind to cell-free DNA present during sepsis.

Learn about the history of gene editing and explore how these experiments not only pushed the field forward, but how they also held us back.